How to Source Non-IMP Supplies for Clinical Trials
Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP...
Sandoz Abandons US Development of Rixathon
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to...
GDPR: The Implications for Clinical Development
Eight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on...
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges...
Medical Device Development – Challenges of an SME
John Shillingford, Clinical Operations Director, Orsus Medical, describes the inherent challenges facing small- to mid-sized...
MDMA Treatments Found to Eliminate PTSD Symptoms in Phase II Trial
Gavin Davidson, CVMD Analyst, GlobalData, examines how MDMA is used to treat patients with PTSD
How Whole Systems Thinking Could Transform the Clinical Supply Chain
Hedley Rees, Chief Disruptor, PharmaFlow, discusses the need for a rethink on supply chain processes
Managing Blinding Requirements in IRT: An Overview
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded...
Industry Viewpoints: Clinical Trials in Asia – Key Considerations
Mainfong Ang, Amgen, sits down with CTA’s Jisong Seo about the difficulties of clinical operations...
Integrating New Assets: A Supply Chain Perspective
Barrett Glasser, Associate Director, Clinical Drug Supply, Biogen, provides an overview on how to on...